Hematology TimesTwo agents could take AML therapy in new directionsJune 7, 2018Leukemia, Myelodysplasia, TransplantationAML
Hematology NewsIvosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AMLJune 3, 2018AMLLeukemia, Myelodysplasia, Transplantation
Hematology TimesFDA grants priority review to gilteritinib for R/R AMLMay 30, 2018Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology NewsFDA to review FLT3 agent for refractory AMLMay 29, 2018AMLLeukemia, Myelodysplasia, Transplantation
Hematology TimesProtein may be therapeutic target for AMLMay 21, 2018Leukemia, Myelodysplasia, TransplantationAML
Hematology TimesNCCN releases guidelines for AML patientsMay 15, 2018Leukemia, Myelodysplasia, TransplantationAML
Hematology TimesCAR T-cell therapy bridges to HSCT in AML patientMay 9, 2018Leukemia, Myelodysplasia, TransplantationTransplantationAML
Hematology TimesY chromosome gene protects against AMLMay 8, 2018Leukemia, Myelodysplasia, TransplantationAML
Hematology NewsImproving survival in older AML patientsApril 26, 2018AMLLeukemia, Myelodysplasia, Transplantation
Hematology TimesPotential therapeutic target for type of AMLApril 25, 2018Leukemia, Myelodysplasia, TransplantationAML
Hematology TimesGO approved to treat AML in EuropeApril 24, 2018Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesArt education benefits blood cancer patientsApril 23, 2018AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingTransplantationAML
Hematology TimesBET inhibitor has lasting effects in AML, MMApril 21, 2018Leukemia, Myelodysplasia, TransplantationMultiple MyelomaAML
Hematology TimesInhibitor outperforms rivals in leukemia, lymphomaApril 20, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
